Antibody-guided irradiation of malignant pleural and pericardial effusions.

Tumour-associated monoclonal antibodies (HMFG1, HMFG2 and AUA1) radiolabelled with iodine-131 were given intracavitary (intrapleurally and intrapericardially) to patients with malignant effusions. Ten out of 13 effusions (3 pericardial and 7 pleural) responded completely with no fluid reaccumulation...

Descripción completa

Detalles Bibliográficos
Autores principales: Pectasides, D., Stewart, S., Courtenay-Luck, N., Rampling, R., Munro, A. J., Krausz, T., Dhokia, B., Snook, D., Hooker, G., Durbin, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1986
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001403/
https://www.ncbi.nlm.nih.gov/pubmed/3718827
Descripción
Sumario:Tumour-associated monoclonal antibodies (HMFG1, HMFG2 and AUA1) radiolabelled with iodine-131 were given intracavitary (intrapleurally and intrapericardially) to patients with malignant effusions. Ten out of 13 effusions (3 pericardial and 7 pleural) responded completely with no fluid reaccumulation between 3 and 18 months. No clinical or other toxicity was observed. This new method of treatment for recurrent malignant effusions is non-toxic and effective resulting in improved quality of life, and, in some cases, prolongation of survival.

Ejemplares similares